肾移植受者急性排斥反应后的长期结局:ANZDATA分析
该研究基于澳大利亚和新西兰透析与移植登记处1997至2017年间13,614例首次肾移植受者数据,分析移植后6个月内急性排斥反应与后续移植物丢失及死亡的关系。结果显示急性排斥反应发生率为21.4%,与慢性移植物肾病所致移植物丢失、6个月后再发排斥反应、带功能移植物死亡及心血管病和癌症死亡风险升高相关。
要点
- 急性排斥反应与慢性移植物肾病所致移植物丢失风险升高相关(HR 1.39)。
- 急性排斥反应与6个月后再发排斥反应风险升高相关(HR 1.85)。
- 急性排斥反应与心血管病死亡(HR 1.30)和癌症死亡(HR 1.35)风险升高相关。
核心结论
- 急性排斥反应与肾移植受者远期移植物失败和死亡风险增加相关,尤其是心血管病和癌症死亡。
研究设计与样本
- 基于澳大利亚和新西兰透析与移植登记处的回顾性队列分析,纳入1997至2017年间13,614例首次肾移植且移植物功能维持至少6个月的受者。
主要发现
- 急性排斥反应发生于2906例受者(21.4%)。
- 急性排斥反应与慢性移植物肾病所致移植物丢失相关(HR 1.39;95%CI 1.23至1.56)。
- 急性排斥反应与6个月后再发排斥反应相关(HR 1.85;95%CI 1.39至2.46)。
- 急性排斥反应与带功能移植物死亡相关(HR 1.22;95%CI 1.08至1.36)。
- 急性排斥反应与心血管病死亡(HR 1.30;95%CI 1.11至1.53)和癌症死亡(HR 1.35;95%CI 1.12至1.64)相关。
临床怎么用
- 急性排斥反应仍是肾移植临床和试验中需监测的重要短期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Declining rates of acute rejection (AR) and the high rate of 1-year graft survival among patients with AR have prompted re-examination of AR as an outcome in the clinic and in trials. Yet AR and its treatment may directly or indirectly affect longer-term outcomes for kidney transplant recipients. METHODS: To understand the long-term effect of AR on outcomes, we analyzed data from the Australia and New Zealand Dialysis and Transplant Registry, including 13,614 recipients of a primary kidney-only transplant between 1997 and 2017 with at least 6 months of graft function. The associations between AR within 6 months post-transplant and subsequent cause-specific graft loss and death were determined using Cox models adjusted for baseline donor, recipient, and transplant characteristics. RESULTS: AR occurred in 2906 recipients (21.4%) and was associated with graft loss attributed to chronic allograft nephropathy (hazard ratio [HR], 1.39; 95% confidence interval [95% CI], 1.23 to 1.56) and recurrent AR beyond month 6 (HR, 1.85; 95% CI, 1.39 to 2.46). Early AR was also associated with death with a functioning graft (HR, 1.22; 95% CI, 1.08 to 1.36), and with death due to cardiovascular disease (HR, 1.30; 95% CI, 1.11 to 1.53) and cancer (HR, 1.35; 95% CI, 1.12 to 1.64). Sensitivity analyses restricted to subgroups with either biopsy-proven, antibody-mediated, or vascular rejection, or stratified by treatment response produced similar results. CONCLUSIONS: AR is associated with increased risks of longer-term graft failure and death, particularly death from cardiovascular disease and cancer. The results suggest AR remains an important short-term outcome to monitor in kidney transplantation and clinical trials.
引用
- Clayton PA, McDonald SP, Russ GR, et al. Long-Term Outcomes after Acute Rejection in Kidney Transplant Recipients: An ANZDATA Analysis. J Am Soc Nephrol. 2019. PMID: 31308074. doi:10.1681/ASN.2018111101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。